Kezar Life Sciences, Inc. (KZR) News

Kezar Life Sciences, Inc. (KZR): $2.86

0.15 (+5.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add KZR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 373

in industry

Filter KZR News Items

KZR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest KZR News From Around the Web

Below are the latest news stories about KEZAR LIFE SCIENCES INC that investors may wish to consider to help them evaluate KZR as an investment opportunity.

Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 05, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted six employees nonqualified stock options to purchase 232,000 shares of its common stock with an exercise price of $3.05 per share, which is equal to the closing price of Kezar’s common s

Yahoo | April 5, 2023

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., March 14, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Yahoo | March 14, 2023

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

SOUTH SAN FRANCISCO, Calif., March 13, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.

Yahoo | March 13, 2023

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

SOUTH SAN FRANCISCO, Calif., March 06, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

Yahoo | March 6, 2023

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complement/Inflammation panel discussion at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 am ET in Boston, MA.

Yahoo | March 1, 2023

A Kezar Life Sciences, Inc. (NASDAQ:KZR) insider increased their holdings by 9.9% last year

Insiders were net buyers of Kezar Life Sciences, Inc.'s ( NASDAQ:KZR ) stock during the past year. That is, insiders...

Yahoo | February 6, 2023

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., January 04, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.

Yahoo | January 4, 2023

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

SOUTH SAN FRANCISCO, Calif., November 14, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

Yahoo | November 14, 2022

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., November 11, 2022--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 30,000 shares of its common stock with an exercise price of $7.06 per share, which is equal to the closing price of Kezar’s common

Yahoo | November 11, 2022

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., November 10, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Yahoo | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7375 seconds.